Neumora Therapeutics Inc., a clinical-stage biopharmaceutical company, announced its financial results for the first quarter ending March 31, 2025. The company reported a net loss of $68.0 million, compared to a net loss of $53.7 million for the same period in 2024. As of March 31, 2025, Neumora's cash, cash equivalents, and marketable securities totaled $249.4 million. The company expects its current cash position, combined with a $20 million draw from a $125 million venture debt facility secured from K2 HealthVentures, to support operations into 2027. In terms of business operations, Neumora continues to advance its pipeline of therapeutics for brain diseases. The company is progressing with the Phase 1b signal-seeking study of NMRA-511 in Alzheimer's disease agitation and has resumed enrollment for the KOASTAL-3 and -2 studies for major depressive disorder, with topline data expected in 2026. Additionally, Neumora plans to advance its M4 positive allosteric modulator $(PAM)$ program into the clinic by mid-2025.